Download PDF
Exp Clin Endocrinol Diabetes 2017; 125(07): 449-453
DOI: 10.1055/s-0043-103968
Article
© Georg Thieme Verlag KG Stuttgart · New York

Influence of the SLCO1B3 Gene on Sulfonylurea Failure in Patients with Type 2 Diabetes in China

Qian Ren
1   Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, P. R. China
,
Xueyao Han
1   Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, P. R. China
,
Jin Ren
1   Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, P. R. China
,
Xinyu Liu
1   Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, P. R. China
,
Linong Ji
1   Department of Endocrinology and Metabolism, Peking University People’s Hospital, Beijing, P. R. China
› Author Affiliations
Further Information

Publication History

received 06 December 2016
revised 10 February 2017

accepted 14 February 2017

Publication Date:
25 April 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Background

Sulfonylureas are widely used class of drugs for the treatment of type 2 diabetes (T2DM). Recent research has demonstrated that SLCO1B3 functions as a determinant of the insulinotropic effect of glibenclamide at the tissue level. However, whether this gene can influence the efficacy of glibenclamide in type 2 diabetic patients is not currently well-understood.

Methods

All of our study subjects were enrolled from the Xiaoke Pills Clinical Trial. The subjects were treated with glibenclamide, and followed for 48 weeks. The rs4149117 genotype (T334G) in the SLCO1B3 gene was identified by direct sequencing. Relationships between genotype and efficacy and safety outcomes were evaluated by logistic or linear regression models as appropriate.

Results

A total of 374 subjects were enrolled in this study. The average age was 54.4±8.9 years, the percentage of males was 52.9%, and 91% of participants finished the genotype analysis successfully. Logistic regression analysis demonstrated that there was no significant difference between genotype and treatment failure of glibenclamide under an additive genetic model after adjusting for age, sex, renal function and diabetes duration (OR=1.009, 95% CI 0.692–1.473, P=0.961). The linear regression model demonstrated that the rs4149117 mutation in SLCO1B3 was significantly associated with a reduction in FPG after 48 weeks of treatment, independent of age, sex, renal function and diabetes duration (P=0.017, beta=0.130). In safety outcome analysis, we observed that rs4149117 had no association with hypoglycaemia.

Conclusions

The rs4149117 mutation in the SLCO1B3 gene is not associated with sulfonylurea efficacy.

Key words

pharmacogenetics - sulfonylurea efficacy - hypoglycaemia - type 2 diabetes
 

  • References

  • 1 Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-754
    CrossrefPubMedGoogle Scholar
  • 2 China Diabetes Society . China Guideline For Type 2 Diabetes. ed. Li Xiaoyun. Peking: Peking University Medical Publisher; 2013: 1-104
    Google Scholar
  • 3 American Diabetes Association . Standards of medical care in diabetes-2017. Diabetes Care 2017; 40: S1-S135
    CrossrefPubMedGoogle Scholar
  • 4 Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes: A patient-centered ap- proach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
    CrossrefPubMedGoogle Scholar
  • 5 Menon KN, Seshadri MS. Secondary failure to sulfonylureas in NIDDM. Are sulfonylureas still useful?. J Assoc Physicians India 1990; 38: 533-534
    PubMedGoogle Scholar
  • 6 Hirst JA, Farmer AJ, Dyar A. et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis. Diabetologia 2013; 56: 973-984
    CrossrefPubMedGoogle Scholar
  • 7 Sesti G, Laratta E, Cardellini M. et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5’-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 2334-2339
    CrossrefPubMedGoogle Scholar
  • 8 Feng Y, Mao G, Ren X. et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008; 31: 1939-1944
    CrossrefPubMedGoogle Scholar
  • 9 Pearson ER, Donnelly LA, Kimber C. et al. Variation in TCF7 L2 influences therapeutic response to sulfonylureas: A GoDARTs study. Diabetes 2007; 56: 2178-2182
    CrossrefPubMedGoogle Scholar
  • 10 Schroner Z, Javorsky M, Tkacova R. et al. Effect of sulphonylurea treatment on glycaemic control is related to TCF7 L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 89-91
    PubMedGoogle Scholar
  • 11 Schroner Z, Dobrikova M, Klimcakova L. et al. Variation in KCNQ1 is associated with therapeutic response to sulphonylureas. Med Sci Monit 2011; 17: CR392-CR396
    PubMedGoogle Scholar
  • 12 Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011; 12: 1161-1191
    CrossrefPubMedGoogle Scholar
  • 13 Ragia G, Petridis I, Tavridou A. et al. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009; 10: 1781-1787
    CrossrefPubMedGoogle Scholar
  • 14 Zhou K, Donnelly L, Burch L. et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: A Go-DARTS study. Clin Pharmacol Ther 2010; 87: 52-56
    CrossrefPubMedGoogle Scholar
  • 15 Subramanian M, Agrawal V, Sandee D. et al. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics 2012; 22: 590-597
    CrossrefPubMedGoogle Scholar
  • 16 Ragia G, Tavridou A, Elens L. et al. CYP2C9 *2 allele increases risk for hypoglycemia in POR *1/ *1 type 2 diabetic patients treated with sulfonylureas. Exp Clin Endocrinol Diabetes 2014; 122: 60-63
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Meyer Zu Schwabedissen HE, Boettcher K, Steiner T. et al. OATP1B3 is expressed in pancreatic beta-islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide. Diabetes 2014; 63: 775-784
    CrossrefPubMedGoogle Scholar
  • 18 Ji L, Tong X, Wang H. et al. Efficacy and safety of traditional chinese medicine for diabetes: A double-blind, randomised, controlled trial. PloS one 2013; 8: e56703
    CrossrefPubMedGoogle Scholar
  • 19 Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004; 14: 441-452
    CrossrefPubMedGoogle Scholar
  • 20 Geng F, Jiao Z, Dao YJ. et al. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. Clin Chim Acta 2012; 413: 683-690
    CrossrefPubMedGoogle Scholar
  • 21 Boivin AA, Cardinal H, Barama A. et al. Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients. Drug Metab Pharmacokinet 2013; 28: 274-277
    CrossrefPubMedGoogle Scholar
  • 22 Choi JR, Kim JO, Kang DR. et al. Genetic variations of drug transporters can influence on drug response in patients treated with docetaxel chemotherapy. Cancer Res Treat 2015; 47: 509-517
    PubMedGoogle Scholar
  • 23 de Lima LT, Bueno CT, Vivona D. et al. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients. Hematology 2015; 20: 137-142
    CrossrefPubMedGoogle Scholar
  • 24 Maruthur NM, Gribble MO, Bennett WL. et al. The pharmacogenetics of type 2 diabetes: A systematic review. Diabetes Care 2014; 37: 876-886
    CrossrefPubMedGoogle Scholar
  • 25 Bachmakov I, Glaeser H, Fromm MF. et al. Interaction of oral antidiabetic drugs with hepatic uptake transporters: Focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 2008; 57: 1463-1469
    CrossrefPubMedGoogle Scholar